CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
CASI Pharma (CASI) Misses Q1 EPS by 5c, Revenues Beat
May 13, 2021 7:10 AM EDTCASI Pharma (NASDAQ: CASI) reported Q1 EPS of ($0.11), $0.05 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $5.74 million versus the consensus estimate of $5.05 million.
Wei-Wu He, Ph.D., CASI's Chairman, and Chief Executive Officer, commented, "We are pleased to report $5.7 million EVOMELA® revenues for the quarter. For the full year 2021, we... More
